Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

178 Applying Pharmacogenomics in Therapeutics
53. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM,
et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine
methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther.
2013;93(4):324–5.
54. Yang JJ, Lim JYS, Huang J, et al. The role of inherited TPMT and COMT genetic
variation in cisplatin-induced ototoxicity in children with cancer. Nature. 2013;​
94(2):252–9.
55. Ross CJD, Katzov-Eckert H, Dube MP. Genetic variants in TPMT and COMT are associated
with hearing loss in children receiving cisplatin chemotherapy. Nature. 2009;​
41(12):1345–49.
56. TheraGuide 5-FU, Myriad Genetics Laboratories. Available from: http://www.myriadtests.
com/hcp/theraguide_testing_process.htm (accessed August 18, 2014).
57. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M.
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine
dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther.
2013;94(6):640.
58. Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor
of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Arthritis Rheumat. 2004;50:2202–10.
59. Goetz MP, Murdter TE, Winter S. Tamoxifen use in postmenopausal breast cancer:
CYP2D6 matters. J Clin Oncol. 2013;31(2):176–80.
60. Goetz MP, Suman V, Ames M, et al. Tamoxifen pharmacogenetics of CYP2D6,
CYP2C19, and SULT1A1: Long term follow-up of the North Central Cancer Treatment
Group 89-30-52 adjuvant trial. [Abstract] 31st Annual San Antonio Breast Cancer
Symposium, December 10–14, 2008, San Antonio, TX, A-6037, 2008.
61. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms
and outcomes among women with early stage breast cancer treated with tamoxifen.
JAMA. 2009;302(13):1429–36.
62. Brauch H, Murdter TE, Eichelbaum M, et al. Pharmacogenomics of tamoxifen therapy.
Clin Chem. 2009;55(10):1770–82.
63. Ferradlceschi R, Newman WG. The impact of CYP2D6 genotyping on tamoxifen treatment.
Pharmaceuticals. 2010;3:1122–38.
64. Elitek [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2011.
65. Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase
administration. Ann Pharmacother. 2005;39:1932–35.
66. Beutler E. G6PD deficiency. Blood. 1994;84:3613–36.
67. Tafinlar [package insert]. Research Triangle Park, NC: Glaxo Smith Kline; 2014.
68. Sharom F. ABC multidrug transporters: Structure, function and role in chemoresistance.
Pharmacogenomics. 2008;9:105–27.
69. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human
multidrug-resistance gene: Multiple sequence variations and correlation of one allele
with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;​
97:3473–78.
70. Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome
in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955–62.
71. Kao CH, Hsieh JF, Tsai SC, et al. Quickly predicting chemotherapy response to
paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m
methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin
Cancer Res. 2000;6:820–4.
72. Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino-acid 482 in the ABCG2
gene affect substrate and antagonist specificity. Br J Cancer. 2003;89:1971–78.
73. Herceptin [package insert]. South San Francisco, CA: Genentech; 2015.